These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32160847)

  • 1. Structural And Computational Perspectives of Selectively Targeting Mutant Proteins.
    Coban MA; Fraga S; Caulfield TR
    Curr Drug Discov Technol; 2021; 18(3):365-378. PubMed ID: 32160847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugging "undruggable" genes for cancer treatment: Are we making progress?
    Duffy MJ; Crown J
    Int J Cancer; 2021 Jan; 148(1):8-17. PubMed ID: 32638380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Mutant KRAS for Anticancer Therapy.
    Chen F; Alphonse MP; Liu Y; Liu Q
    Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting mutant KRAS.
    Erlanson DA; Webster KR
    Curr Opin Chem Biol; 2021 Jun; 62():101-108. PubMed ID: 33838397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue.
    Perurena N; Cichowski K
    Cancer Cell; 2024 Jun; 42(6):943-945. PubMed ID: 38861932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covalent targeting of acquired cysteines in cancer.
    Visscher M; Arkin MR; Dansen TB
    Curr Opin Chem Biol; 2016 Feb; 30():61-67. PubMed ID: 26629855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIP5K1A: a potential target for cancers with KRAS or TP53 mutations.
    East MP; Laitinen T; Asquith CRM
    Nat Rev Drug Discov; 2020 Jul; 19(7):436. PubMed ID: 32332925
    [No Abstract]   [Full Text] [Related]  

  • 10. Direct KRAS inhibition: progress, challenges, and a glimpse into the future.
    Grapsa D; Syrigos K
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):437-440. PubMed ID: 32320301
    [No Abstract]   [Full Text] [Related]  

  • 11. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
    Nyíri K; Koppány G; Vértessy BG
    Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Discovery by Targeting Mutant KRAS.
    Ye N
    Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
    [No Abstract]   [Full Text] [Related]  

  • 14. KRASG12C inhibitor: combing for combination.
    Chakraborty A
    Biochem Soc Trans; 2020 Dec; 48(6):2691-2701. PubMed ID: 33242077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
    Porru M; Pompili L; Caruso C; Biroccio A; Leonetti C
    J Exp Clin Cancer Res; 2018 Mar; 37(1):57. PubMed ID: 29534749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efforts to Develop KRAS Inhibitors.
    Holderfield M
    Cold Spring Harb Perspect Med; 2018 Jul; 8(7):. PubMed ID: 29101115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the MAPK Pathway in KRAS-Driven Tumors.
    Drosten M; Barbacid M
    Cancer Cell; 2020 Apr; 37(4):543-550. PubMed ID: 32289276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wild type p53 function in p53
    Sundar D; Yu Y; Katiyar SP; Putri JF; Dhanjal JK; Wang J; Sari AN; Kolettas E; Kaul SC; Wadhwa R
    J Exp Clin Cancer Res; 2019 Feb; 38(1):103. PubMed ID: 30808373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
    Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
    Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.